Herold Advisors Inc. Sells 1,033 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Herold Advisors Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,288 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the period. Herold Advisors Inc.’s holdings in Gilead Sciences were worth $591,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in GILD. Strategic Blueprint LLC grew its holdings in Gilead Sciences by 8.1% during the 3rd quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 328 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Gilead Sciences during the third quarter worth about $207,000. Koshinski Asset Management Inc. grew its holdings in shares of Gilead Sciences by 5.1% during the third quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 145 shares in the last quarter. Harrington Investments INC grew its holdings in shares of Gilead Sciences by 2.2% during the third quarter. Harrington Investments INC now owns 20,786 shares of the biopharmaceutical company’s stock worth $1,558,000 after purchasing an additional 450 shares in the last quarter. Finally, Verity & Verity LLC grew its holdings in shares of Gilead Sciences by 0.8% during the third quarter. Verity & Verity LLC now owns 333,109 shares of the biopharmaceutical company’s stock worth $26,539,000 after purchasing an additional 2,708 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Oppenheimer reissued an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a report on Friday, April 19th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday. Finally, StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. Eleven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $83.87.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.2 %

GILD stock traded up $0.15 during midday trading on Friday, hitting $65.42. The company had a trading volume of 12,349,126 shares, compared to its average volume of 7,477,028. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52 week low of $64.63 and a 52 week high of $87.86. The stock’s 50 day moving average price is $71.28 and its 200 day moving average price is $76.25. The stock has a market cap of $81.45 billion, a price-to-earnings ratio of 14.54, a PEG ratio of 1.20 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.2 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.